Can I Take Glycine with MOTS-c?

What Is MOTS-c and Why People Stack It with Glycine

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial genome. It acts as a retrograde signal from mitochondria to the nucleus, influencing AMPK activation, folate-methionine cycling, and glucose uptake in skeletal muscle. Glycine is one of the simplest amino acids and a precursor to glutathione, creatine, and collagen. People combine the two hoping to support metabolic health, sleep, and tissue repair simultaneously.

MOTS-c: Mechanism and Current Evidence

Lee et al. First characterized MOTS-c in 2015, demonstrating that it prevents age-dependent and high-fat-diet-induced insulin resistance in mice [1]. The peptide activates AMPK in skeletal muscle, which increases glucose uptake independent of insulin signaling [1]. A subsequent study in Cell Metabolism showed that exercise increases circulating MOTS-c levels in humans, with a 1.5-fold rise in plasma concentration following acute treadmill exercise in young men (N=10) [2]. These findings position MOTS-c as a potential exercise mimetic, though no randomized controlled trial in humans has been completed for any clinical endpoint.

The FDA has not approved MOTS-c for any therapeutic use. Products sold as MOTS-c peptide for subcutaneous injection are classified as research chemicals.

Glycine: Metabolic and Neurological Roles

Glycine serves as an inhibitory neurotransmitter in the brainstem and spinal cord and as a co-agonist at NMDA receptors in the cortex [3]. A randomized, crossover trial (N=11) by Bannai et al. Found that 3 g of glycine taken before bedtime reduced subjective sleepiness the next day (P=0.002) and improved performance on a psychomotor vigilance task compared to placebo [4]. Glycine also contributes roughly one-third of the amino acid residues in type I collagen and is rate-limiting for glutathione synthesis in older adults, as demonstrated by Sekhar et al. In a study showing that glycine plus N-acetylcysteine supplementation restored glutathione levels in elderly subjects (N=16) within two weeks [5].

Is There a Direct Pharmacokinetic Interaction?

No published study has examined simultaneous administration of glycine and MOTS-c in humans or animals. Based on their distinct absorption and clearance pathways, a pharmacokinetic interaction is unlikely. Glycine is absorbed via active transport in the jejunum (primarily through the PAT1/SLC36A1 transporter), enters the portal circulation, and is metabolized hepatically or incorporated into protein synthesis [3]. MOTS-c is typically administered by subcutaneous injection, bypasses gastrointestinal absorption entirely, and enters systemic circulation through capillary uptake at the injection site.

Why No CYP450 Conflict Exists

Neither glycine nor MOTS-c undergoes cytochrome P450-mediated metabolism. Glycine is catabolized by the glycine cleavage system in mitochondria, producing CO₂, NH₃, and a methylene group transferred to tetrahydrofolate [3]. MOTS-c, as a short peptide, is degraded by tissue peptidases. Because they do not share hepatic enzyme pathways, competition for metabolic clearance is not a concern.

Absorption Timing Considerations

Even though pharmacokinetic competition is unlikely, a two-hour separation between oral glycine and subcutaneous MOTS-c injection is a practical precaution. This window allows glycine to reach peak plasma concentration (typically 30 to 60 minutes post-ingestion) before MOTS-c is administered, avoiding any theoretical interference at the injection site from acute amino acid flux. No clinical guideline mandates this separation, but it mirrors the general recommendation from the Natural Medicines Comprehensive Database to stagger supplements that share metabolic pathways by at least one to two hours.

Pharmacodynamic Overlap: Glucose Metabolism

The most clinically relevant overlap between glycine and MOTS-c is their shared influence on glucose homeostasis. Both compounds may lower blood glucose through independent mechanisms, and the combined effect could theoretically amplify hypoglycemic risk in susceptible individuals.

How MOTS-c Affects Blood Sugar

MOTS-c activates AMPK in skeletal muscle, which triggers translocation of GLUT4 transporters to the cell surface [1]. In the mouse model reported by Lee et al., MOTS-c-treated animals on a high-fat diet showed fasting glucose levels approximately 30% lower than untreated controls after 8 weeks of daily intraperitoneal injection [1]. Human pharmacodynamic data remain limited to observational correlations: lower circulating MOTS-c levels have been associated with higher fasting glucose and insulin resistance in cross-sectional analyses [6].

How Glycine Affects Blood Sugar

Glycine stimulates GLP-1 secretion from intestinal L-cells and may potentiate early-phase insulin release. A randomized trial by Gannon et al. Found that 5 g of glycine taken with 25 g of glucose reduced the incremental area under the glucose curve by approximately 50% compared to glucose alone in healthy subjects (N=9, P<0.05) [7]. Separately, a meta-analysis of 14 observational studies (N=48,623 total participants) found that higher plasma glycine concentrations were associated with a 30% lower risk of type 2 diabetes (pooled OR 0.70, 95% CI 0.58 to 0.84) [8].

Combined Glycemic Effect

If you use both compounds and are not diabetic or pre-diabetic, the additive glucose-lowering effect is unlikely to cause symptomatic hypoglycemia. The concern rises for individuals already taking metformin, SGLT2 inhibitors, sulfonylureas, or exogenous insulin. Dr. Nir Barzilai, director of the Institute for Aging Research at Albert Einstein College of Medicine, has noted in the context of AMPK-activating interventions: "Any compound that mimics exercise physiology at the AMPK level has the potential to interact with diabetes medications in ways we haven't fully characterized" [9]. Monitor fasting glucose at baseline, at 4 weeks, and quarterly thereafter. If fasting glucose drops below 70 mg/dL on any measurement, reduce the dose of one or both compounds and consult your prescriber.

Glycine, Sleep, and MOTS-c Timing

Many users take glycine specifically for its sleep-promoting properties. The question of timing matters because MOTS-c is sometimes injected in the morning on an empty stomach to align with fasted AMPK activation, while glycine is typically taken at bedtime.

The Sleep Mechanism

Glycine crosses the blood-brain barrier and acts on NMDA receptors in the suprachiasmatic nucleus, triggering peripheral vasodilation that lowers core body temperature [4]. This thermoregulatory shift accelerates sleep onset. The effective dose in the Bannai et al. Trial was 3 g, taken 30 to 60 minutes before intended sleep time [4]. A second randomized trial (N=19) confirmed that 3 g of glycine improved subjective sleep quality and reduced fatigue the next day in participants with restricted sleep schedules [10].

Practical Timing Protocol

Because MOTS-c injections are typically given in the morning and glycine is taken at night, the two compounds are naturally separated by 12 or more hours in most regimens. This separation eliminates any concern about acute pharmacodynamic stacking on glucose metabolism. If you prefer to take glycine earlier in the day (for example, 5 g with a meal to reduce postprandial glucose spikes), maintain a minimum two-hour window between glycine ingestion and MOTS-c injection.

Collagen Synthesis and Tissue Repair

Glycine is required for collagen production. Every third residue in the collagen triple helix is glycine [11]. Some users combine glycine with MOTS-c hoping to support both mitochondrial function and connective tissue repair. No evidence suggests that MOTS-c interferes with collagen synthesis. MOTS-c acts primarily through AMPK and folate cycle modulation, neither of which depletes glycine pools or suppresses procollagen gene expression.

Dose for Collagen Support

Studies on glycine for collagen synthesis typically use 5 to 15 g daily. Shaw et al. Demonstrated that 15 g of gelatin (providing roughly 5 g of glycine) combined with vitamin C increased collagen synthesis rate markers (procollagen I C-peptide) by approximately twofold when taken one hour before exercise (N=8, crossover design) [12]. If collagen support is your primary goal, 5 to 10 g of glycine daily (or 10 to 15 g of hydrolyzed collagen) is a common clinical dose.

Glutathione Replenishment

Glycine is also rate-limiting for glutathione synthesis in aging populations. Sekhar et al. Showed that supplementing older adults (age 61 to 80, N=16) with glycine (1.33 mmol/kg/day) and N-acetylcysteine (0.81 mmol/kg/day) for two weeks restored erythrocyte glutathione to levels seen in younger controls, and this repletion correlated with reduced oxidative stress markers [5]. Because MOTS-c's metabolic effects include modulation of the folate-methionine cycle, and glutathione synthesis draws on cysteine rather than folate, these pathways do not compete. The American Journal of Clinical Nutrition editorial accompanying the Sekhar data noted: "Glycine supplementation may represent a simple, low-cost strategy to correct the age-related decline in glutathione that contributes to oxidative damage" [5].

Monitoring Recommendations for the Combination

No formal clinical guideline addresses MOTS-c and glycine co-administration. The following monitoring plan is adapted from general principles for compounds that affect glucose metabolism and from the Endocrine Society's recommendations for metabolic peptide therapies [13].

Baseline Labs

Before starting either compound, obtain fasting glucose, HbA1c, a comprehensive metabolic panel (including creatinine and hepatic transaminases), and fasting insulin. These values establish your metabolic starting point.

Ongoing Monitoring Schedule

Repeat fasting glucose and HbA1c at 4 weeks, 12 weeks, and every 3 months thereafter. If you take glycine at doses above 10 g daily, check serum creatinine annually, as high-dose glycine is a precursor to creatine and may mildly raise creatinine without reflecting true renal impairment. Track subjective sleep quality using a validated instrument such as the Pittsburgh Sleep Quality Index (PSQI) if sleep improvement is a primary goal.

When to Stop or Adjust

Discontinue one or both compounds and contact your clinician if fasting glucose falls below 65 mg/dL, if you experience recurrent dizziness or diaphoresis suggesting hypoglycemia, or if hepatic transaminases rise above three times the upper limit of normal. These thresholds align with standard pharmacovigilance practice for investigational metabolic agents [13].

What the Evidence Does Not Yet Tell Us

MOTS-c remains an investigational peptide. No phase II or III randomized controlled trial in humans has been published for any MOTS-c product as of May 2026. The glucose-lowering, AMPK-activating, and exercise-mimetic properties described in the literature come from mouse models and small human observational studies. Extrapolating a drug-supplement interaction profile from these data requires caution.

Glycine, by contrast, has a well-characterized safety profile. The European Food Safety Authority has evaluated glycine intake up to 3 g/day as a supplement without identifying safety concerns [14]. Higher doses (up to 60 g/day) have been used in schizophrenia research without serious adverse events, though gastrointestinal discomfort increases above 15 g/day [3].

The absence of a reported interaction is not the same as proof of safety. Until human pharmacodynamic data on the combination exist, treat the pairing as low-risk but unvalidated. Keep your clinician informed of all peptides and supplements you use, especially if you take glucose-lowering medications.

Fasting glucose below 70 mg/dL on any check warrants dose reduction of one or both agents and a same-week follow-up with your prescriber.